I really thought this week’s news would get biotech stock CEL-SCI (CVM) moving again. And it did…..for a while. We saw little follow-through on the chart though. Even so, CEL-SCI is still one of our favorite longer-term ideas.

If you didn’t hear, CEL-SCI announced they’ve discovered an effective treatment for rheumatoid arthritis. They’re calling it CEL-2000 for now; it’s a vaccine/peptide that so far seems to be as effective - if not more effective - than the leading RA treatment. That’s not to say CEL-2000 is ready for the market. It’s got a lot more R&D to go, not to mention it has to pass the FDA’s requirements as well. But still, it’s something they feel confident enough about to keep working on. The rheumatoid arthritis market is no minor market either - it’s worth $13 billion per year.

Now, if the CEL-SCI news is only a little bit familiar to you, it may be because we’ve primarily focused on their cancer treatment Multikine. It’s also a vaccine, but obviously one with a much bigger impact on a market with much stronger demand. We haven’t been able to tell you much about Multikine’s progress lately because, well, there’s not much to report. The wrapped up Phase II testing last year, and will start Phase III testing later this year. Once this last round of trials gets underway, we’ll certainly have more to talk about.

The CEL-2000 announcement is equally good news…just different. Keep in mind, however, that Multikine is closer to the end of its developmental cycle, while CEL-2000 is practically at the beginning of its creation.

As for the stock, the last time I looked I was looking mostly at its range-boundedness (which I know is not a word, but you know what I’m saying). Here it is more than two months later, and the story is still the same despite a brief glimpse of bullishness on Tuesday…stuck between 65 and 70 cents. That’s still the key to getting this one going again - a break past 70 cents. Give it time.

Are you a subscriber to the Small Cap Network newsletter? If not, you’re missing out on some great trading ideas and exclusive market commentary. To sign up, just go to the top right corner of any page of our website. You’ll be joining thousands of other subscribers who have already benefited from our news and views.